The
global Mesenchymal Stem Cells Market size is expected to
reach USD 7.21 billion by 2030. The market is expected to reach at a CAGR of
12.8% from 2023 to 2030. An exponential increase in Mesenchymal Stem Cell (MSC)
based research and its implications in the field of regenerative medicine is
anticipated to fuel the industry expansion. Moreover, the constantly evolving
landscape of cell therapies is also anticipated to propel investments in the
mesenchymal stem cells market space; large-scale operational firms are
targeting small or emerging players with an operating strategy of acquisition
to bolster their market presence.
The
strong pipeline of mesenchymal stem cell-based products coupled with emerging
applications of mesenchymal stem cells is anticipated to accelerate the
industry growth. For instance, in 2022, the U.S.FDA has approved around
19 stem cell therapies for range of life-threatening disorders. Some
of these therapies include, BREYANZI of BMS, ALLOCORD, KYMIRAH of Novartis etc.
Moreover, a substantial number of companies are exploring the potential of MSCs
as therapeutic regime for the management of inflammatory conditions, in turn,
boosting market growth.
For
instance, on January 2022, the Century Therapeutics and Bristol Myers Squibb
entered a collaboration to expand IPSC-derives allogenic cell therapies. In
addition, Takeda/TiGenix phase 3 clinical trial incorporated
mesenchymal stem cells for complex perianal fistulas in Crohn's Disease. This
was the most successful late-stage clinical trial as of September 2020. In
addition, in August 2022 AGC Biologics partnered with human mesenchymal stem
cell supplier, RoosterBio Inc. to deliver clinically proven advanced therapies
for life-threatening conditions. These factors are projected to bolster the
usage of stem cell products offered by key entities, thereby intensifying the
market competition.
Market
players are focused on the expansion of their offerings through extensive
R&D and the formation of alliances and partnerships with other major
players to sustain their market position. Owing to the recent pandemic of
COVID-19, several research and academic research institutes are making focused
efforts to develop a treatment regime by using mesenchymal stem cells.
Related Press
Release@ Mesenchymal Stem Cells Market Report
Mesenchymal Stem Cells Market Report Highlights
- The products
segment dominated the segment and accounted for the largest revenue share
of 78.8% in 2022. Among the products, the cells and cell lines segment has
emerged as a key contributor to the segment’s revenue
- Based on
workflow type, the culture and cryopreservation segment dominated the
industry with revenue share of 44.5% in 2022. The segment growth is
attributed to the high demand for cryopreservation services and
enhancement of healthcare infrastructure in developing economies
- The
allogenic MSCs segment accounted for the higher revenue share of 56.6% in
2022. This is attributed to the high safety profile of allogeneic
mesenchymal stem cells in clinical applications
- The bone
marrow segment dominated the market and accounted for the largest revenue
share of 24.52% in 2022. Bone marrow is a major source of isolation for
mesenchymal cells
- The disease
modelling application segment dominated the application and accounted for
the largest revenue share of 35.1% in 2022. The use of cellular disease
models with patient specific MSCs provides an ideal tool for pathological
research
- North
America dominated the market and accounted for the largest revenue share
of 44.28% in 2022. The higher revenue share of the region is accounted to
supportive government legislation and rising application of cell therapies
in chronic disorders
List of Key Players in the Mesenchymal Stem Cells
Market
- Thermo
Fisher Scientific, Inc
- Cell
Applications, Inc
- Axol
Biosciences Ltd
- Cytori
Therapeutics Inc
- STEMCELL
Technologies
- Cyagen
Biosciences
- Celprogen
Inc
- BrainStorm
Cell Limited
- Stemedica
Cell Technologies Inc
- Merck KGaA
(MilliporeSigma)
- PromoCell
GmbH
Mesenchymal Stem Cells Market Report Scope
Report Attribute |
Details |
Market size value in 2023 |
USD 3.10 billion |
Revenue forecast in 2030 |
USD 7.21 billion |
Growth Rate |
CAGR of 12.8% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Related Reports@
Stem
Cells Market
Human
Embryonic Stem Cells Market
Mesenchymal Stem Cells Market Segmentation
Grand
View Research has segmented the global mesenchymal stem cells market based on
products and services, workflow, type, source of isolation, indication,
application, and region:
Mesenchymal Stem Cells Product & Services
Outlook (Revenue, USD Million, 2018 - 2030)
- Products
- Cells &
Cell Lines
- Kits,
Media, & Reagents
- Others
- Services
Mesenchymal Stem Cells Workflow Outlook (Revenue,
USD Million, 2018 - 2030)
- Cell
Sourcing & Isolation
- Culture
& Cryopreservation
- Differentiation
- Characterization
Mesenchymal Stem Cells Type Outlook (Revenue, USD
Million, 2018 - 2030)
- Autologous
- Allogeneic
Mesenchymal Stem Cells Source of Isolation Outlook
(Revenue, USD Million, 2018 - 2030)
- Bone Marrow
- Cord Blood
- Peripheral
Blood
- Fallopian
Tube
- Fetal Liver
- Lung
- Adipose
Tissues
Mesenchymal Stem Cells Indication Outlook (Revenue,
USD Million, 2018 - 2030)
- Bone And
Cartilage Repair
- Cardiovascular
Disease
- Inflammatory
And Immunological Diseases
- Liver
Diseases
- Cancer
- GvHD
- Others
Mesenchymal Stem Cells Application Outlook (Revenue,
USD Million, 2018 - 2030)
- Disease
Modelling
- Drug
Development & Discovery
- Stem Cell
Banking
- Tissue
Engineering
- Toxicology
Studies
- Others
Mesenchymal Stem Cells Regional Outlook (Revenue,
USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-95196
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment